Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

RNase H2, mutated in Aicardi‐Goutières syndrome, resolves co-transcriptional R-loops to prevent DNA breaks and inflammation

Autor: Cristini, A, Tellier, M, Constantinescu, F, Accalai, C, Albulescu, LO, Heiringhoff, R, Bery, N, Sordet, O, Murphy, S, Gromak, N

Publikováno v: Nature Communications. 13

RNase H2 is a specialized enzyme that degrades RNA in RNA/DNA hybrids and deficiency of this enzyme causes a severe neuroinflammatory disease, Aicardi Goutières syndrome (AGS). However, the molecular mechanism underlying AGS is still unclear. Here,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa6302f78f62eb9255d35730464e3073
https://doi.org/10.1038/s41467-022-30604-0

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe

Autor: Bery, N, Legg, S, Debreczeni, J, Breed, J, Embrey, K, Stubbs, C, Kolasinska-Zwierz, P, Barrett, N, Marwood, R, Watson, J, Tart, J, Overman, R, Miller, A, Phillips, C, Minter, R, Rabbitts, T

Publikováno v: Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
Nature Communications

Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions that interact with signalling effector proteins. Here, we report designed ankyrin repeat proteins (DARPins) macromolecules that specifically inhibit the KRAS i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7f7163bbf36c94cde3cd6851fc26d090
https://doaj.org/article/d60832bba2a448e1bd87fa3edb2b14fd

Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds

Autor: Cruz-Migoni, A, Canning, P, Quevedo, C, Bataille, C, Bery, N, Miller, A, Russell, A, Phillips, S, Carr, S, Rabbitts, T

Publikováno v: 'Proceedings of the National Academy of Sciences of the USA ', vol: 116, pages: 2545-2550 (2019)
Proceedings of the National Academy of Sciences of the United States of America

Significance The RAS family of oncogenic proteins is important as therapy targets because of the frequency of activating mutations in almost all major cancers. An important approach is development of small molecules with drug-like properties that can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::55ab417c69a21f2b0cf74bf649d2e154
https://ora.ox.ac.uk/objects/uuid:a3b1db0c-a649-4914-885d-cd906c33d6af